Challenges and opportunities to enhance global drug development in neonates
Alexandra M Smith1, Jonathan M Davis
1Department of Pediatrics, Tufts Clinical and Translational Research Institute, The Floating Hospital for Children at Tufts Medical Center, Boston, MA, USA.
Insights
Despite legislative efforts, many Neonatal Intensive Care Unit (NICU) medications lack Food and Drug Administration (FDA) approval. International collaborations are crucial for advancing neonatal drug development and improving patient outcomes.
Area of Science:
- Neonatal pharmacology
- Regulatory science
- Pediatric drug development
Background:
- Federal regulations over 15 years have aimed to boost pediatric and neonatal drug development.
- A significant number of medications used in Neonatal Intensive Care Units (NICUs) are not FDA-approved for neonatal use.
- Investigational challenges hinder the progress of neonatal clinical trials.
Purpose of the Study:
- To review the historical context of neonatal drug development.
- To examine recent legislative initiatives promoting therapeutic agent studies in neonates.
- To outline future strategies for advancing drug development in neonates.
Main Methods:
- Review of historical data and legislative efforts.
- Analysis of challenges in neonatal clinical trials.
- Examination of consortia-led initiatives.
Main Results:
- Many NICU medications remain unapproved by the FDA for neonatal use, despite regulatory efforts.
- The Critical Path Institute, in collaboration with the FDA, has established consortia like the International Neonatal Consortium and Pediatric Trials Consortium.
- These consortia aim to overcome challenges by fostering global interaction among researchers, regulators, and industry to generate high-quality, regulatory-ready data.
Conclusions:
- Neonatal drug development requires focused attention to enhance patient outcomes.
- International collaborations and multidisciplinary teams are key to accelerating efficient, high-quality neonatal research.
- Sharing data, knowledge, and expertise through these collaborations can drive medical innovation and advance regulatory science.
Purpose Of Review:
This study reviews the history of neonatal drug development, recent legislative efforts designed to facilitate the study of therapeutic agents in neonates, and future steps necessary to advance drug development.
Recent Findings:
Although many federal regulations have been introduced over the past 15 years to encourage pediatric and neonatal drug development, the majority of medications that are used in the Neonatal Intensive Care Unit are not approved by the Food and Drug Administration (FDA) for use in neonates. There are many challenges that investigators encounter in conducting neonatal clinical trials. The Critical Path Institute working in conjunction with the FDA has developed several consortia, including the International Neonatal Consortium and Pediatric Trials Consortium, to address these concerns and facilitate interactions of researchers, regulators, funding agencies, industry, and others across the globe to produce regulatory ready and high quality data for neonatal therapeutics.
Summary:
Neonatal drug development is an area which deserves significant attention if we hope to continue to improve outcomes. With the help of international collaborations, it is possible to accelerate efficient and high quality neonatal research through multidisciplinary teams that share data, knowledge, and expertise to advance medical innovation and regulatory science.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
01:21Factors Affecting Drug Response: Overview
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:29Drug Dosing: Infants and Children